Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70080 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Ryota Ozawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Introduction
Chemoimmunotherapy is widely used as the first‐line management of advanced non‐small cell lung cancer (NSCLC) in clinical settings. However, predictive factors associated with the development of immune‐related adverse events (irAEs) and prognostic factors for NSCLC patients undergoing chemoimmunotherapy remains largely unexplored. Therefore, in this study, we aimed to evaluate predictive factors for irAE development and prognostic factors associated with chemoimmunotherapy in NSCLC patients.
Methods
This study enrolled 199 patients with advanced and recurrent NSCLC who underwent chemoimmunotherapy across eight institutions in Nagano prefecture from December 2018 to January 2023. We examined predictive factors associated with irAE development and prognostic factors associated with overall survival (OS).
Results
Among the patients, 106 experienced irAEs, while 93 patients did not. A total of 44 (22.1%) patients developed multiple irAEs. High serum albumin levels (Alb >3.5 g/dL) emerged as an independent predictive factor associated with irAE development in logistic regression analysis (odds ratio; 2.35, 95% confidence interval 1.27–4.34, p = 0.007). Furthermore, the development of multiple irAEs ( p = 0.016), lower lactate dehydrogenase level (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Nagano Red Cross Hospital, Nagano, Japan.
- Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
- Department of Respiratory Medicine, Suwa Red Cross Hospital, Suwa, Japan.
- Department of Respiratory Medicine, Nagano Municipal Hospital, Nagano, Japan.
- Department of Respiratory Medicine, National Hospital Organization Shinshu Ueda Medical Center, Ueda, Japan.
- Department of Respiratory Medicine, Iida Municipal Hospital, Iida, Japan.
ORCID-Profile: Kei Sonehara, Taisuke Araki
Zitieren
APA
Ozawa, R., Sonehara, K., Hachiya, T., Nozawa, S., Agatsuma, T., Yamamoto, H., Kato, A., Matsuo, A., Hirabayashi, T., Araki, T., Komatsu, M., Tateishi, K., & Hanaoka, M. (2024). Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.70080
Vancouver
Ozawa R, Sonehara K, Hachiya T, Nozawa S, Agatsuma T, Yamamoto H, et al. Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study. Cancer Medicine. 2024. doi:10.1002/cam4.70080
BibTeX
@article{Ozawa2024,
author = {Ozawa, Ryota and Sonehara, Kei and Hachiya, Tsutomu and Nozawa, Shuhei and Agatsuma, Toshihiko and Yamamoto, Hiroshi and Kato, Akane and Matsuo, Akemi and Hirabayashi, Taro and Araki, Taisuke and Komatsu, Masamichi and Tateishi, Kazunari and Hanaoka, Masayuki},
title = {Evaluation of the association between predictive factors and the development of immune‐related adverse events and prognostic factors for chemoimmunotherapy in patients with non‐small cell lung cancer: A multicenter retrospective study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70080}
}
EUVIMED